Pfizer Deal History & Licensing Activity
Pfizer is a large pharma headquartered in US. Over the past three years, Pfizer has been involved in 41 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (12 deals). The company currently has 50 active clinical trials, primarily in Metabolic.
Deals (12mo)
2
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Metabolic
Pfizer Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Pfizer in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| bispecific immuno-oncology assets | 3SBio | Bispecific Antibodies | Unknown | option | Jul 18, 2026 |
| SSGJ-707 (PD-1/VEGF bispecific) | 3SBio / Shenyang Sunshine | Bispecific Antibodies | Unknown | license | Jul 12, 2026 |
| Innovent cancer drugs | Innovent Biologics | Antibodies | Unknown | collaboration | Jul 1, 2026 |
| Undisclosed asset | YaoPharma | Other | Unknown | license | Jun 15, 2026 |
| Up to 12 antibody drugs in oncology | Innovent | Antibodies | Unknown | collaboration | Jun 15, 2026 |
| 12-program antibody-based oncology collaboration | Innovent Biologics | Antibodies | Discovery | collaboration | May 15, 2026 |
| Matrix-M | Novavax | Other | Unknown | license | Apr 7, 2026 |
| YP05002 | YaoPharma | Small Molecules | Phase 1 | license | Dec 9, 2025 |
| YP05002 | YaoPharma Co., Ltd. | Small Molecules | Phase 1 | license | Dec 9, 2025 |
| YP05002 | Chongqing Yao Pharmaceutical Company (YaoPharma) | Small Molecules | Phase 1 | collaboration | Dec 9, 2025 |
Showing 10 of 15 recent transactions. Upgrade to Pro for full deal history with financials.
Pfizer Pipeline Focus
Therapeutic areas and modalities where Pfizer is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Pfizer Strategic Signals
Key indicators of Pfizer's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Revenue at Risk (LOE)
Patent expirations create urgency for Pfizer to replace revenue through in-licensing or acquisitions.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Pfizer Clinical Pipeline
Pfizer has 50 active clinical trials across 5 development phases.
14
Unknown
3
Not Applicable
13
Phase 1
10
Phase 2
10
Phase 3
See How Your Asset Matches Pfizer's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Pfizer Licensing & Deal Activity
Pfizer is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 41 deals over the past three years, Pfizer ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Pfizer include Metabolic (21 deals and trials), Solid Tumors (15 deals and trials), Oncology (12 deals and trials), and Infectious Disease (6 deals and trials). In terms of modality, Pfizer has shown particular interest in bispecific antibodies, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Pfizer and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Pfizer's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.